SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sonnet BioTherapeutics Holdings, Inc. (SONN) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 43/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SONN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio5.14
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.95
Book Value / Share$0.00
Revenue / Share$0.25
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-269,068.00 |
$41.7M |
$-9.08M |
-21.8% |
| 2017 |
$-175,138.00 |
$41.43M |
$-6.79M |
-16.4% |
| 2018 |
$-126,904.00 |
$30.73M |
$-6.85M |
-22.3% |
| 2019 |
$-163,753.00 |
$40.61M |
$-5.03M |
-12.4% |
| 2020 |
$-17,159.00 |
$0.00 |
$-31.06M |
- |
| 2021 |
$-2,507.83 |
$483.63K |
$-25.01M |
-5170.5% |
| 2022 |
$-1,203.05 |
$349.94K |
$-29.77M |
-8508.3% |
| 2023 |
$-145.12 |
$147.81K |
$-18.83M |
-12741.6% |
| 2024 |
$-11.35 |
$18.63K |
$-7.44M |
-39929.3% |
| 2025 |
$-3.95 |
$1M |
$-16.11M |
-1611.3% |
